PBAC's latest decision on Rifampicin: Recommended (2020). Considered for Treatment of Mycobacterium ulcerans infection (Buruli ulcer) in combination with another antibiotic.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2020
Submissions
1
2020 → 2020
Eligible population
Patients with Mycobacterium ulcerans infection (Buruli ulcer) requiring treatment in combination with another antibiotic.
Therapy area
Infectious disease
Line of therapy
Any
Evidence base
Single-arm
Economic model
Not modelled
Eligible patients/year
409
ICER note
No economic evaluation or ICER calculated. This is a minor submission (extension of indication to an already-listed drug with no new economic model).